Cancer Survival in Sweden 1960–1998 Developments Across Four Decades

Talbäck, Mats; Stenbeck, Magnus; Rosén, Måns; Barlow, Lotti; Glimelius, Bengt

doi:10.1080/02841860310013391

Cited by 91 publications

(73 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Population-based monitoring of cancer patient survival is an important task of cancer registries (e.g. Berrino et al, 1995Berrino et al, , 1999Berrino et al, , 2003Dickman et al, 1999;Talbäck et al, 2003). As with other cancer statistics, the validity of population-based cancer survival estimates depends on the quality of the cancer registry data.…”

mentioning

confidence: 99%

Population-based monitoring of cancer patient survival in situations with imperfect completeness of cancer registration

Brenner¹,

Hakulinen

2005

Br J Cancer

View full text Add to dashboard Cite

Selective underascertainment of cases may bias estimates of cancer patient survival. We show that the magnitude of potential bias strongly depends on the time periods affected by underascertainment and on the type of survival analysis (cohort analysis vs period analysis). We outline strategies on how to minimise or overcome potential biases. Population-based monitoring of cancer patient survival is an important task of cancer registries (e.g. Berrino et al, 1995Berrino et al, , 1999Berrino et al, , 2003Dickman et al, 1999;Talbäck et al, 2003). As with other cancer statistics, the validity of population-based cancer survival estimates depends on the quality of the cancer registry data. Most obviously, a minimum requirement is reliable follow-up of patients with respect to vital status. The validity of survival estimates may also depend on completeness of cancer registration (Monnet et al, 1998;Prior et al, 1998). In particular, selective underascertainment of patients with a good prognosis may lead to underestimation of cancer patient survival, whereas an opposite effect could result from selective underascertainment of patients with poor prognosis. The aim of this paper is to assess the impact of various patterns of incompleteness of cancer registration on population-based estimates of cancer patient survival in a quantitative manner. MATERIAL AND METHODS DatabaseOur analysis is based on data from the nationwide Finnish Cancer Registry whose true completeness (in terms of ascertainment of both incident cases and follow-up status) is known to be very close to 100% (Teppo et al, 1994). We included patients, aged 15 years or older, with a first diagnosis of one of the six most common forms of cancer in Finland between 1990 and 1999. Statistical analysisThe impact of underascertainment of incident cases was assessed for 5-year relative survival rates (Ederer et al, 1961), which were derived using Hakulinen's (1982) method by two different approaches illustrated in Figure 1. With the first approach, 5-year survival rates were calculated for the cohort of patients diagnosed in 1990 -1994 and followed with respect to vital status until the end of 1999 (solid frame). The second approach is the so-called period analysis, which has first been proposed a few years ago to provide more up-to-date estimates of cancer patient survival Gefeller 1996, 1997). Here, 5-year relative survival estimates for the 1995 -1999 period are reported, which exclusively reflect the survival experience of patients during those years (dashed frame).To assess the impact of incompleteness of registration either in the earlier or in the more recent years of the database, we carried out both a cohort analysis for the 1990 -1994 cohort and a period analysis for the 1995 -1999 period, assuming underascertainment of the following cases either in 1990 -1994 or in 1995 -1999 in different scenarios: (a) all cases, (b) only cases dying within 5 years following diagnosis and (c) only cases still alive 5 years following diagnosis.Expected survival estimate...

show abstract

mentioning

confidence: 99%

Population-based monitoring of cancer patient survival in situations with imperfect completeness of cancer registration

Brenner¹,

Hakulinen

2005

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…One contributing factor to the poor prognosis is the fact that the majority of patients do not seek medical attention until the tumor has already gained substantial volume or even disseminated [5]. Only a subpopulation of patients seems to benefit from treatment, which is generally either surgery or a combination of radiation and chemotherapy for localized tumors.…”

Section: Introductionmentioning

confidence: 99%

Activation of Growth Factor Receptors in Esophageal Cancer—Implications for Therapy

et al. 2007

View full text Add to dashboard Cite

Esophageal cancer is a highly aggressive disease and is the seventh most common cause of cancer-related death in the western world. Worldwide, it ranks as the sixth most frequent cause of cancer death. Despite advances in surgical techniques and treatment, the prognosis of esophageal cancer remains poor, with very few longterm survivors. The need for novel strategies to detect esophageal cancer earlier and to improve current therapy is urgent.It is well established that growth factors and growth factor receptor-mediated signaling pathways are important components of the transformation process in many forms of cancer, including esophageal cancer. With the recent advances in drug development, there are emerging possibilities to use growth factor signal transduction pathways in targeted therapy. This review provides a summary of the role of growth factors and their receptors in esophageal cancer and discusses their potential roles as biomarkers and as targets in therapy.

show abstract

“…Over the decades the widespread usage in rectal surgery of total mesorectal excision (TME) procedures popularized by Heald and Ryall [42], together with neoadjuvant chemoradiotherapy protocols in advanced cases, have lowered local recurrence rates and improved survival [43][44][45]. Similar trends remain unobserved in colon cancer, and patients with colon cancer now have a worse prognosis than those with rectal cancer even though they more frequently undergo adjuvant chemotherapy [46][47][48][49]. Cancer statistics in the United States as well as in Europe show that in the past 20 years the survival rates for rectal cancer have overtaken those for colon cancer [50,51].…”

Section: Proactive Management Of Peritoneal Metastases From Colorectamentioning

confidence: 76%

Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Sammartino

Biacchi

Cornali

et al. 2016

Indian J Surg Oncol

View full text Add to dashboard Cite

An integrated treatment strategy using peritonectomy procedures plus hyperthermic intraperitoneal chemotherapy (HIPEC) is now a clinical standard of care in selected patients with peritoneal metastases and primary peritoneal tumors. This comprehensive approach can offer many patients, who hitherto had no hope of cure, a good quality of life and survival despite limited morbidity. The increasingly successful results and chance of interfering in the natural history of disease has prompted research to develop for some clinical conditions a therapeutic strategy designed to prevent malignant peritoneal dissemination before it becomes clinically evident and treat it microscopically (tertiary prevention). The main factor governing successful cytoreductive surgery and predicting outcome is the extent of peritoneal spread assessed with the peritoneal cancer index (PCI). In peritoneal metastases from colorectal and gastric cancer the PCI score acquires a specific role acting as the cut-off between patients who can undergo curative surgery or palliation. Long-term results show that the only group enjoying favorable results are patients with limited disease (a statistical minority). By applying to appropriately selected patients with primary malignancies a proactive management strategy including HIPEC we can treat patients with microscopic peritoneal dissemination and therefore at PCI 0. Among treated conditions pseudomyxoma peritonei enjoys the best results. But a major future advance comes from identifying among lesions at major risk of pseudomyxoma.

show abstract

Cancer Survival in Sweden 1960–1998 Developments Across Four Decades

Cited by 91 publications

References 32 publications

Population-based monitoring of cancer patient survival in situations with imperfect completeness of cancer registration

Population-based monitoring of cancer patient survival in situations with imperfect completeness of cancer registration

Activation of Growth Factor Receptors in Esophageal Cancer—Implications for Therapy

Proactive Management for Gastric, Colorectal and Appendiceal Malignancies: Preventing Peritoneal Metastases with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Contact Info

Product

Resources

About